Indian government supports development of Panacea's H1N1 vaccine
This article was originally published in Scrip
Executive Summary
Panacea Biotec, India's second-largest producer of vaccines, has been granted financial assistance of Rs100 million ($2.2 million) from the country's department of biotechnology for the development of its H1N1 vaccine.
You may also be interested in...
Bharat Biotech Plans Coronavirus Vaccine
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
SARS-CoV-2 Variants And Current Vaccines: “It’s Not All Or Nothing”
Experts including renowned virologist Peter Piot, FDA’s Peter Marks and CEPI’s Richard Hatchett discussed multiple dimensions pertaining to coronavirus variants and existing vaccines at a recent conference, noting enhanced post-deployment surveillance is underway in the US. While there’s no need to panic for every variant that emerges, equitable access to vaccines is critical to ensure that gains made over last year are not undone, they said.
Merck & Co, Indian Firms On Tackling Supply Chain Risks And A Hijack
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.
Need a specific report? 1000+ reports available
Buy Reports